文献速递炎症性肠病

完全内镜下愈合与炎症性肠病停用抗TNF后较低复发风险相关

Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-08-31

这项多中心前瞻性研究纳入81例荷兰炎症性肠病患者,均在无激素临床缓解且内镜下愈合后停用抗TNF。中位随访2.0年,49%复发;部分愈合者12个月复发率70% vs 完全愈合者35%(aHR 3.28,95%CI 1.43-7.50)。UC/IBDU患者使用美沙拉秦与复发减少相关(aHR 0.08,95%CI 0.01-0.67)。

要点

  • 内镜下愈合后停用抗TNF仍有较高复发风险,中位随访2.0年复发率49%
  • 部分内镜愈合者12个月复发率70%,完全愈合者35%(aHR 3.28)
  • UC/IBDU患者使用美沙拉秦与复发减少相关(aHR 0.08)

核心结论

  • 内镜下愈合的IBD患者停用抗TNF后复发风险高,但多数患者重新使用抗TNF后可恢复缓解。
  • 完全内镜愈合和UC/IBDU患者使用美沙拉秦可降低复发风险。

研究设计与样本

  • 多中心前瞻性研究,纳入81例成人CD、UC或IBDU患者(CD n=41,51%)。
  • 患者均有≥6个月无激素临床缓解(基线确认)且内镜下愈合(Mayo<2/SES-CD<5且无大溃疡),于2018至2020年在荷兰停用抗TNF。
  • 采用Kaplan-Meier和Cox回归分析评估复发率及预测因素。

主要发现

  • 中位随访2.0年(IQR 1.6-2.1),40例(49%)复发,CD与UC/IBDU患者复发率相当。
  • 12个月时,部分内镜愈合者复发率70% vs 完全内镜愈合者35%(aHR 3.28;95%CI 1.43-7.50)。
  • UC/IBDU患者使用美沙拉秦与复发减少相关(aHR 0.08;95%CI 0.01-0.67)。
  • 30例重新开始抗TNF治疗,3个月时73%恢复临床缓解。

关键数值与推荐

  • 部分内镜愈合定义:Mayo 1/SES-CD 3-4;完全内镜愈合定义:Mayo 0/SES-CD 0-2。
  • 内镜愈合定义:Mayo<2/SES-CD<5且无大溃疡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Discontinuation of anti-tumor necrosis factor-α treatment (anti-TNF) (infliximab and adalimumab) in patients with inflammatory bowel disease (IBD) is associated with a high relapse risk that may be influenced by endoscopic activity at the time of stopping. We assessed the relapse rate after anti-TNF withdrawal in patients with endoscopic healing and studied predictors of relapse including the depth of endoscopic healing. METHODS: This was a multicenter, prospective study in adult patients with Crohn's disease (CD), ulcerative colitis (UC), or IBD-unclassified (IBDU), with ≥6 months of corticosteroid-free clinical remission (confirmed at baseline) and endoscopic healing (Mayo <2/SES-CD <5 without large ulcers), who discontinued anti-TNF between 2018 and 2020 in the Netherlands. We performed Kaplan-Meier and Cox regression analyses to assess the relapse rate and evaluate potential predictors: partial (Mayo 1/SES-CD 3-4) versus complete (Mayo 0/SES-CD 0-2) endoscopic healing, anti-TNF trough levels, and immunomodulator and/or mesalamine use. RESULTS: Among 81 patients (CD: n = 41, 51%) with a median follow-up of 2.0 years (interquartile range, 1.6-2.1), 40 patients (49%) relapsed. Relapse rates in CD and UC/IBDU patients were comparable. At 12 months, 70% versus 35% of patients with partial versus complete endoscopic healing relapsed, respectively (adjusted hazard rate [aHR], 3.28; 95% confidence interval [CI], 1.43-7.50). Mesalamine use was associated with fewer relapses in UC/IBDU patients (aHR, 0.08; 95% CI, 0.01-0.67). Thirty patients restarted anti-TNF, and clinical remission was regained in 73% at 3 months. CONCLUSIONS: The relapse risk was high after anti-TNF withdrawal in IBD patients with endoscopic healing, but remission was regained in most cases after anti-TNF reintroduction. Complete endoscopic healing and mesalamine treatment in UC/IBDU patients decreased the risk of relapse.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Mahmoud R, Savelkoul EHJ, Mares W, et al. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022. PMID: 36055567. doi:10.1016/j.cgh.2022.08.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。